Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Priya, Rastogi"'
Autor:
Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen R. D. Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to p
Externí odkaz:
https://doaj.org/article/1378a75d34cd4a89ad1255e30c08bb59
Autor:
Pooja P. Advani, Kathryn J. Ruddy, Joerg Herrmann, Jordan C. Ray, Emily C. Craver, Greg Yothers, Reena S. Cecchini, Corey Lipchik, Huichen Feng, Priya Rastogi, Eleftherios P. Mamounas, Sandra M. Swain, Charles E. Geyer, Norman Wolmark, Soonmyung Paik, Katherine L. Pogue-Geile, Gerardo Colon-Otero, Edith A. Perez, Nadine Norton
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe cardiotoxic effects of doxorubicin, trastuzumab, and other anticancer agents are well known, but molecular genetic testing is lacking for the early identification of patients at risk for therapy-related cardiac toxicity.MethodsUsing the
Externí odkaz:
https://doaj.org/article/0bd121bdd57c4d5fb05b24d6e6c5fc77
Autor:
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort st
Externí odkaz:
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Autor:
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether this impact varies by
Externí odkaz:
https://doaj.org/article/ed8c22cdd63b4d8ab3a69bbf18ba9909
Autor:
Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John P. Crown, Michael P. Thirlwell, David M. Ellison, Jean-Francois Boileau, Patrick J. Flynn, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH was evaluated by questions related to hysterectomy, oophorectomy, and reported men
Externí odkaz:
https://doaj.org/article/2fe38dd1eb3c43a496b8bd443b9c9acc
Autor:
Priya Rastogi, Gong Tang, Saima Hassan, Charles E. Geyer, Catherine A. Azar, Gustav C. Magrinat, J. Marie Suga, Harry D. Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Francois Boileau, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark
Publikováno v:
Breast Cancer Research and Treatment. 199:243-252
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3316050f3862d0e0d35a0f432943113
https://doi.org/10.1007/s10549-023-06881-8
https://doi.org/10.1007/s10549-023-06881-8
Autor:
Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara Tolaney, Matthew P. Goetz, Hope Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valerie Andre, Nadia Harbeck, Miguel Martín
Publikováno v:
Cancer Research. 83:GS1-09
Background Adjuvant abemaciclib (a CDK4 and 6 inhibitor) combined with ET resulted in significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients (pts) with HR+, HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5198a4f524def42f0c4897053805a305
https://doi.org/10.1158/1538-7445.sabcs22-gs1-09
https://doi.org/10.1158/1538-7445.sabcs22-gs1-09
Autor:
Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Publikováno v:
Cancer Research. 83:GS1-04
Introduction: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the differential effect of endocrine therapy (ET) vs chemotherapy followed by endocrine therapy (CET), including the impact of menopausal st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aed5f4e5e36b8c13ea14b757c669bbee
https://doi.org/10.1158/1538-7445.sabcs22-gs1-04
https://doi.org/10.1158/1538-7445.sabcs22-gs1-04
Autor:
Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios (Terry) Mamounas, Charles E. Geyer Jr, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:P1-04
Background: The primary aim of the NRG Oncology/NSABP B-52 clinical trial was to test if estrogen deprivation (ED) administered concomitantly with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), would improve the pCR rate in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c8da7ae6e2fcddb9030f0d11adc75f1
https://doi.org/10.1158/1538-7445.sabcs22-p1-04-10
https://doi.org/10.1158/1538-7445.sabcs22-p1-04-10
Autor:
Marianna Chavez, Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz, Eleftherios (Terry) Mamounas, Soonmyung Paik, Hanna Bandos, Wajeeha Razaq, Anne O’Dea, Virginia Kaklamani, Andrea L.M. Silber, Lisa E. Flaum, Eleni Andreopolu, Joseph Baar, Albert G. Wendt, Jennifer F. Carney, Priyanka Sharma, Julie R. Gralow, Danika L. Lew, William E. Barlow, Gabriel N. Hortobagyi
Publikováno v:
Cancer Research. 83:GS1-07
BACKGROUND: Abnormalities of the PI3kinase/AKT/mTOR signaling network are common in breast cancer (BC) and are associated with endocrine resistance. Everolimus, an mTOR-inhibitor increased PFS when combined with endocrine therapy (ET) in the metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6142bc2cc1670e425728ac8bf52a759
https://doi.org/10.1158/1538-7445.sabcs22-gs1-07
https://doi.org/10.1158/1538-7445.sabcs22-gs1-07